Whitepaper: Accelerate antibody screening and characterisation
Posted: 24 August 2021 | Sartorius AG | No comments yet
This whitepaper overviews use of Advanced Flow Cytometry to accelerate antibody screening and characterisation and reveal deeper biological insights.
The iQue® Advanced Flow Cytometry Platform is designed specifically for high-throughput, large-scale screening, hence is the ideal platform for antibody discovery workflows.
This white paper reviews how biopharmaceutical companies, Takeda Pharmaceuticals, Avacta Life Sciences, AbX Biologics and Ablynx, (a Sanofi company), are using the iQue® Advanced Flow Cytometry Platform for high throughput antibody screening and characterisation workflows.
Related content from this organisation
- Engineering cell lines for rare disease research and precision therapeutics
- Sartorius Launches the Octet® SF3 SPR System, Strengthening its Leadership in Advanced Label-Free Bioanalytics
- The growth of cell line development
- Ensuring the safety and efficacy of biologics products
- Human biopsies in nanofibrillar cellulose hydrogel – a novel method for long-term tissue culture
Related topics
Antibodies, Antimicrobials, Assays, Biomarkers, Biopharmaceuticals, Cell Cultures, Disease Research, Hit-to-Lead, Immunology, Personalised Medicine, Regenerative Medicine, Screening, Stem Cells, Targets, Toxicology
Related organisations
Sartorius AG